Understanding Telix, page-993

Wonder what this is/was investigating ... ?

Telix Pharmaceuticals LimitedACN 616 620 369Suite 401, 55 Flemington RoadNorth MelbourneVictoria, 3051AustraliaPage 1Telix Pharmaceuticals and Merck Group Combination Therapy CollaborationMelbourne (Australia), Darmstadt (Germany) – 1 Aug 2019. Telix Pharmaceuticals Limited(ASX.TLX, “Telix”) a clinical-stage biopharmaceutical company focused on the developmentof diagnostic and therapeutic products based on “molecularly-targeted radiation” (MTR) hastoday disclosed that it has entered into a research collaboration agreement with MerckHealthcare KGaA (“MRK”). This disclosure is made in accordance with Telix’s reportingobligations under ASX Listing Rule 3.1.Under the terms of the agreement, Telix and MRK will conduct combination studies withseveral MRK molecules in combination with two (2) of Telix’s MTR therapeutic programs. Theagreement provides Telix with access to MRK molecules for use in a mutually agreed researchplan to evaluate combination efficacy in models relevant to clinical translation. The agreementincludes industry-standard collaborative intellectual property provisions. No Telix intellectualproperty rights have been granted to MRK at this time. Any follow-on clinical collaboration issubject to the outcomes of the initial research and will be governed by a separate clinical trialagreement to be agreed between the parties.As the research is commercial-in-confidence, the molecules and oncology focus areas are notdisclosed at this time.


Made me think of it when i saw this this morning ....

By Adam L. Cataldo Merck said its blockbuster cancer drug Keytruda has been approved for the treatment ofadult patients with primary advanced or recurrent endometrial carcinoma. The Food and Drug Administration approved the use of Keytruda, in combination withcarboplatin and paclitaxel, to treat cancer patients based on data from a Phase 3 trial,Merck said Monday. Keytruda in combination with the other drugs reduced the risk of disease progression ordeath by 40% in patients whose cancer was mismatch repair proficient, and by 70% inpatients whose cancer was mismatch repair deficient, compared with a placebo. The FDA's approval is the third endometrial carcinoma indication and the 40thindication overall for Keytruda in the U.S., Merck said. Write to Adam Cataldo at [email protected]. (END) Dow Jones Newswires June 17, 2024 17:41 ET (21:41 GMT)Copyright(c) 2024 Dow Jones & Company, Inc.Tuesday 18 June 2024 07:41:00.000 AESTTuesday 18 June 2024 07:41:00.000 AEST